Diabetes, Obesity and Metabolism

HOPE for diabetes in the new millennium
pp. 1-2(2)
Author: Donnelly R.

Effects of inhibition of the renin-angiotensin system on the cardiovascular actions of insulin
pp. 3-14(12)
Authors: Katovich M.J.; Pachori A.

Is there a role for endothelin antagonists in diabetic renal disease?
pp. 15-24(10)
Authors: Jandeleit-Dahm K.; Allen T.J.; Youssef S.; Gilbert R.E.; Cooper M.E.

Sulphonylurea dose–response relationships: relation to clinical practice
pp. 25-31(7)
Authors: Lindblad U.; Melander A.

Treatment of familial hypertriglyceridaemia with acarbose
pp. 33-38(6)
Authors: Malaguarnera M.; Giugno I.; Ruello P.; Maugeri D.; Pistone G.

Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes new to insulin therapy: experience with insulin lispro
pp. 39-46(8)
Authors: Bastyr E.J.; Huang Y.; Brunelle R.L.; Vignati L.; Cox D.J.; Kotsanos J.G.

Time-course changes in plasma endothelin-1 and its effects on the mesenteric arterial bed in streptozotocin-induced diabetic rats
pp. 47-55(9)
Authors: Makino A.; Kamata K.

Dissociation between Fas expression and induction of apoptosis in human islets of Langerhans
pp. 57-60(4)
Authors: Loweth A.C.; Watts K.; McBain S.C.; Williams G.T.; Scarpello J.H.B.; Morgan N.G.

News and Views
pp. 61-65(5)